Kukje stocks to be rewarding

Published: 2007-10-09 06:56:00

Updated: 2007-10-09 06:56:00

Stocks of Kukje Pharm will continue to provide good opportunities for investors to reap impressive gains going forward given its positive business prospects in the future, said an analyst of Daewoo Securities.

The market outlook for Kukje continues to be rosy, posting an average growth of 10 p...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK